Skip to main content
  • Contact Us
  • Vantage logo Sign Up
  • Subscriber Sign In
Evaluate Logo

navigation

  • COVID-19
    • COVID-19 Update
    • Evaluate Vantage COVID-19 Report
    • COVID-19 Stories from Evaluate Vantage
    • Evaluate’s Business Continuity Plan
  • What We Do
    • Commercial Intelligence
    • Products
      • EvaluatePharma
      • Evaluate Omnium
      • Japan Drug Forecasts
      • European Drug Forecasts
      • Epi Analyzer
    • Evaluate Custom Solutions
    • Evaluate Vantage
      • News
      • Analysis
      • Policy & Pricing
      • Data Insights
      • Events
      • Medtech
      • Therapy Areas
      • Editorial Team
      • About Evaluate Vantage
  • How We Can Help You
    • Pharma and Biotech
    • Medtech
    • Financial Services
    • Management Consultancies
    • Service Providers
    • Customer Testimonials
  • Thought Leadership
  • About Us
    • Press Releases
    • Media Coverage
    • Executive Team
    • Vision & History
    • Careers
      • Current Vacancies
  • Contact Us
  • Sign Up for Evaluate Vantage
  • Subscriber Sign In

 

Vantage logo

Vantage

  • Covid-19
    • Covid-19 Coverage
    • Evaluate Vantage COVID-19 Report
  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Data Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas
  • About
    • Editorial team

Corporate

Thumbnail
January 22, 2021

Apellis takes the complement fight to Astrazeneca

The smaller company believes that its complement C3 inhibitor could make Soliris and Ultomiris redundant in PNH.

Thumbnail
January 22, 2021

Biotech deal premiums still punchy

Article image
Vantage logo
January 21, 2021

Biopharma’s stock market winners and losers in 2020

Article image
Vantage logo
January 20, 2021

2020 drug approvals rise despite Covid-19

Worries about a stricter US FDA come to nothing, as last year’s approval total beats 2019’s.

Article image
Vantage logo
January 21, 2021

Haemonetics and Hillrom deals add to medtech’s 2021 M&A fever

Article image
Vantage logo
January 19, 2021

The pandemic releases its grip on clinical trials

The vast majority of industry-sponsored studies suspended because of Covid-19 resumed quickly, a new analysis finds.

Article image
Vantage logo
January 19, 2021

Aclaris MK2 bears fruit

Aclaris takes a step towards an oral rheumatoid arthritis therapy.

Article image
Vantage logo
January 18, 2021

Aducanumab tops 2021’s biggest potential launches

Blockbuster sales are predicted for several projects nearing approval, from Biogen, Argenx, Fibrogen and others.

Article image
Vantage logo
January 15, 2021

Kinaset takes a sledgehammer to an asthma conundrum

The nascent company hopes to prove that its inhaled pan-Jak is best in class.

Article image
Vantage logo
January 14, 2021

Medtechs rake in the venture cash

In terms of private investments, 2020 was the year of the liquid biopsy.

Article image
Vantage logo
January 13, 2021

After a big year, biotech flotations have much to do

Whether investor enthusiasm for drug stocks holds up this year is the burning question for IPO followers.

  • Load More
We use cookies on this website. By using this site, you agree that we may store and access cookies on your device. Find out more.
Vantage logo
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up

Latest Reports

December 10, 2020

Evaluate Vantage 2021 Preview

July 29, 2020

Evaluate Vantage Pharma, Biotech & Medtech Half-Year Review 2020

View more...

Editor's Picks

Vantage logo
December 10, 2020

What the coming year might hold for biopharma

Vantage logo
December 11, 2020

Covid-19 vaccine developers remind the world that setbacks happen

Vantage logo
December 09, 2020

Astrazeneca’s vaccine looks increasingly like an also-ran

Vantage logo
November 09, 2020

Pfizer and Biontech snatch first Covid vaccine victory

Vantage logo
December 01, 2020

The promise and the perils of antigen testing

Open modal

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-(0)80-1164-4754

Footer menu

  • Terms and Conditions
  • Privacy Policies
  • Cookie Policy

© Copyright 2021 Evaluate Ltd.